KaNDy Therapeutics announces initiation of Phase 2b trial of NT-814 for the treatment of troublesome post-menopausal symptoms

Dr Mike Trower CSO KaNDy Therapeutics will be giving an invited presentation entitled: ‘ Switching off the heat: A novel, rapidly acting and effective non-hormonal approach to treating hot flashes and other symptoms of the menopause with neurokinin-1,3 receptor antagonism’

Contact Us

Please fill out the form to get in touch with us.

Not readable? Change text. captcha txt